In 1950 nearly all British smokers consumed untipped plain cigarettes with mean tar yields of over 30 mg. In 1976, when this study was planned, 88% of cigarettes smoked had filters, and mean tar yields had fallen to around 18 mg; these trends have continued subsequently. By to prevalence of the same four index diagnoses-lung cancer (ICD 162), chronic bronchitis (ICD 491, 492, 496), ischaemic heart disease (ICD 410-414), and 'stroke' (ICD 431-438, excluding subarachnoid haemorrhage)-that Dean had studied. This paper reports the results found and compares them with those from both the earlier studies" and seven more recent ones.5"'1 A more extensive report is available on request from PNL.
Methods and response
The overall design was a case control study of hospital inpatients. For Table 3 presents risks by lifetime history of smoking. In both sexes cigarette smoking was highly significantly associated with lung cancer, chronic bronchitis, and, in the 35-54 age group, ischaemic heart disease. It was not significantly associated with ischaemic heart disease in older subjects or with stroke. Risks of lung cancer and chronic bronchitis were higher, though not significantly, in handrolled than in manufactured cigarette smokers. In the absence of cigarettes, pipe and/or cigar smoking was associated with an increased risk of lung cancer but not of other diseases. Additional analysis showed smoking to be more strongly associated with squamous and small cell lung cancer than with other types of lung cancer.
In table 3, comparisons are based on final diagnosis. Comparison was also made of those whose diagnosis had or had not changed from that provisionally assigned. While some differences in smoking habits were seen, in particular a tendency for control patients originally interviewed as cases to be more often smokers than those originally interviewed as controls, the extent of any potential bias seemed slight (see full report for details).
In both sexes, number of manufactured cigarettes smoked per day at time of heaviest smoking was significantly related to lung cancer, chronic bronchitis, and, in those aged 35-54, ischaemic heart disease. In females, a dose-relation was also seen for ischaemic heart disease in the older age group. The results for ischaemic heart disease showed evidence of conflicting patterns with an advantage to filter cigarette smokers for females and a disadvantage for males. However, no filter/plain differences were seen in either sex when subjects were classified according to smoking habits 10 years before admission.
In an attempt to exclude patients who had altered their smoking habits because of onset of symptoms, analyses were carried out for lung cancer on patients who had not been previously hospitalised and who did not have symptoms of chronic bronchitis. This markedly reduced the number of patients available. The general relation of increased risk to heavy smoking was evident, but no significant reduction in risk in smokers of filter cigarettes was seen.
In table 5, patients who had ever smoked products other than manufactured cigarettes were excluded. In additional analyses, smokers of manufactured cigarettes and other products who had ever smoked filter cigarettes had less than half the risk of lung cancer of those who had never smoked filter cigarettes (R=0.45, p<001). Analyses of all manufactured cigarette smokers and of only those who also smoked other products were also carried out for men for the other diseases, but conclusions were unaffected.
Subjects were categorised by the tar level of the brand of cigarettes smoked 10 years before admission. Though the lowest tar group generally had the lowest risk, the differences within any diagnosis were not marked or very consistent between the sexes, the only analysis showing a significant (p<0-05) trend being for chronic bronchitis in males, where the risk was almost twice 290 Risks oflung cancer, chronic bronchids, ischaemic heart disease, andstroke in reladon to type ofcigarettesmoked 291 as high in smokers of brands with tar yields of 29+ mg as in smokers of brands with tar yields of 17-22 mg.
For lung cancer and ischaemic heart disease, change in number of cigarettes smoked was not related to risk. Risk of chronic bronchitis was higher in those who had recently reduced the number of cigarettes smoked.
No clear relation of inhalation, relighting, tar/nicotine ratio, holding the cigarette in the mouth or butt length to risk of the index diseases was seen; nor were conclusions affected by taking into account any of the wide range of potential confounding variables studied. Details of these and many other analyses carried out are given in the full report.
Discussion
Before attempting to interpret the results, one must consider the validity of the data collected and the possibility of faults in the study design. Considering validity first, it seems from such independent checks as are possible that the data are of the level of accuracy usually obtained in large epidemiological studies. That control patients originally interviewed as cases were somewhat more likely to be smokers than those originally interviewed as controls is consistent with some degree of bias due to patients or interviewers being aware of the diagnosis but may be due to knowledge of smoking habits affecting preliminary diagnosis. More serious are doubts about the validity of the smoking history data; about 10% of the subjects said that they smoked a brand 10 years before admission that was inconsistent with answers to a previous question on the time of switch from plain to filter cigarettes.
It is clear that our control patients, even though not suffering from smoking related diseases, contained relatively more ex-smokers than expected from the general population. Also, the proportion of cigarette smokers reporting smoking plain cigarettes was higher than is seen nationally, not only at admission, but also for the whole 10 years before admission. Whether the factors leading to this discrepancy have also applied to cases is not clear, and this creates difficulty in interpreting the results of the analyses of switching to filter cigarettes. It is not, however, self-evident that comparison with population controls would automatically produce the correct results. This query over the ratio of plain to filter cigarette smokers among the controls has an important bearing on the interpretation of the results for which there is no known correction.
In theory, those who switch to cigarettes with reduced tar and nicotine may "compensate" by either increasing the number of cigarettes smoked daily or by altering the manner of smoking. A number of studies have indicated that compensation by increasing cigarette consumption is, at most, only minimal,"4 and our failure to find any evidence of such an effect confirms this impression. In the present study, it was not possible to check whether the way of smoking had altered intake of tar or nicotine.
Another problem in relating risk to type of cigarette smoked is that there is no time when there are substantial numbers of both smokers of the old high tar plain cigarettes and of smokers of the reduced tar filter cigarettes.
A final problem general to case control studies lies in doubts about their ability to detect other than substantial differences in risk. The method has recently been the subject of considerable criticism. "5 Biases in many such studies may distort the relative risks recorded, while small numbers and errors in the data can reduce the power to detect a real effect. As a rule-of-thumb it is suggested that a well designed case control study should be able to confirm a twofold difference in risk but that, for differences less than this, the power of the study design may be inadequate.
As many have found, the risk of lung cancer, chronic bronchitis, and, particularly in those aged 35-54, ischaemic heart disease was positively associated with the number of manufactured cigarettes smoked daily and was negatively associated with long-term giving up. A number of pieces of evidence suggested that those with an increasing burden of disease are likely to give up smoking or reduce the number of cigarettes they smoke. These include the increased risk in recent ex-smokers of lung cancer (in both sexes) and of ischaemic heart disease (in males), the lack of dependence of risk of chronic bronchitis on whether or not a smoker gave up smoking up to 10 years before admission, and the tendency for risk of chronic bronchitis to be higher for those who reduce the number of cigarettes they smoke than for those who do not.
A review"6 of the effect of type of cigarette on risk of disease emphasised the consistency of the results, despite the diverse nature of the reported studies, noting that generally smokers of filter (or lower tar-nicotine) cigarettes have a lower mortality than smokers of plain (or higher tar-nicotine) cigarettes for those diseases most strongly associated with smoking, and a slightly reduced mortality for those diseases less associated with smoking. It is of interest to compare and contrast findings from the present study and from other studies for each of the four index diagnoses in turn.
For lung cancer, findings from 11 studies"' 7-11 17 provide 20 separate results. Nineteen show a reduced 292 risk in filter or lower tar cigarette smokers, the weighted average relative risk being 0-71 for males and 0*60 for females. In the current study, no evidence of a reduction in risk in relation to filters was seen in male smokers of manufactured cigarettes only, but some evidence of a reduction in risk was seen for those who had never smoked plain cigarettes compared with those who had ever smoked plain cigarettes (a) 
